Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. reports developments across its global biopharmaceutical business, including prescription medicines, vaccines, biosimilars, sterile injectables, and oncology therapies. Recurring news covers financial results and guidance, commercial portfolio changes within Biopharma, dividend declarations, capital allocation priorities, and product access initiatives for established medicines such as Eliquis.
Company updates also address clinical and regulatory activity across Pfizer's pipeline and marketed products. Recent themes include oncology data presentations, Phase 3 results for ELREXFIO in relapsed or refractory multiple myeloma, PADCEV combination regulatory activity in bladder cancer, VYNDAMAX patent litigation settlements, and shareholder meeting communications.
Pfizer (NYSE: PFE) reported positive topline Phase 3 TALAPRO-3 results: TALZENNA plus XTANDI met the primary endpoint with a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) versus placebo plus XTANDI, exceeding the pre-specified hazard ratio target of 0.63.
Consistent benefit was seen in BRCA and non-BRCA HRR gene–mutated metastatic castration-sensitive prostate cancer; an interim analysis showed a strong trend toward improved overall survival. Results will be presented and discussed with global health authorities.
Pfizer (NYSE: PFE) reported positive topline Phase 2 FOURLIGHT-1 results for atirmociclib in HR+, HER2- metastatic breast cancer, meeting the primary endpoint with a 40% reduction in risk of progression or death (HR 0.60; 95% CI 0.440–0.825; p=0.0007).
Results were consistent across prespecified subgroups, >90% of patients started atirmociclib within three months of prior CDK4/6 inhibitor therapy, overall survival was immature (~20% events), and safety was manageable with 6.4% discontinuations due to adverse events. Phase 3 first-line study is ongoing.
Pfizer (NYSE: PFE) reported positive topline Phase 2 results for tilrekimig (PF-07275315) in adults with moderate to severe atopic dermatitis, meeting the primary endpoint with statistically significant EASI-75 improvements at Week 16 across doses.
Placebo-adjusted EASI-75 at Week 16: 38.7% (low), 51.9% (middle), 49.4% (high). Pfizer plans Phase 3 initiation this year and will present detailed results at future medical meetings.
NYSE (NYSE:ICE) issued a pre-market content update on March 4, 2026, featuring market commentary and floor events.
Highlights: a March 4 pre-market briefing by Ashley Mastronardi, an NYSE Live interview with two-time Olympic gold medalist Alysa Liu, Opening Bell partners Ronald McDonald House NY, New York Rangers and RBC Capital Markets, and a Closing Bell by Pfizer (NYSE: PFE).
Pfizer (NYSE: PFE) and Astellas announced Phase 3 EV-304 results showing perioperative PADCEV plus Keytruda cut risk of recurrence/progression or death by 47% versus neoadjuvant gemcitabine+ciplatin (HR 0.53; 95% CI 0.41–0.70; 1-sided p<.0001).
Two‑year event‑free survival was estimated at 79.4% versus 66.2%; overall survival improved (HR 0.65; 95% CI 0.48–0.89; 1-sided p=0.0029) and pathological complete response reached 55.8% versus 32.5% at surgery.
ViiV Healthcare (related to PFE) presented Phase 1 and in-vitro pipeline data at CROI 2026 showing two investigational long-acting HIV therapies with potential for twice-yearly dosing.
VH184, a third-generation INSTI, showed single-dose drug levels up to six months and improved resistance profile versus bictegravir. VH499, a capsid inhibitor, was generally well tolerated and supports ultra long-acting six-month dosing; phase 2b and further studies will define dosing.
ViiV Healthcare (PFE) reported 12-month interim Phase IIb EMBRACE data showing a regimen of intravenous lotivibart (N6LS) every four months plus monthly long-acting cabotegravir maintained viral suppression in 94% (IV) and 82% (SC) of participants versus 88% on standard of care.
The study observed confirmed virologic failures of 4% (n=2/50) IV, 6% (n=3/49) SC, and 4% (n=1/26) standard of care, with lotivibart generally well tolerated and the trial progressing to evaluate a twice-yearly IV dosing interval.
Pfizer (NYSE: PFE) announced FDA full approval (Feb 24, 2026) for BRAFTOVI (encorafenib) in combination with cetuximab and fluorouracil-based chemotherapy for first-line BRAF V600E metastatic colorectal cancer after Phase 3 BREAKWATER results.
Phase 3 mFOLFOX6 data showed a 51% reduction in risk of death and 47% reduction in risk of progression or death versus chemotherapy ± bevacizumab; safety was consistent with known profiles.
Pfizer (NYSE: PFE) invites the public to a webcast of a discussion with Chairman and CEO Albert Bourla at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 10:30 a.m. EST.
Registration and access details are available at www.pfizer.com/investors. The transcript and replay will be posted within 24 hours and remain accessible for at least 90 days.
PFE-linked ViiV Healthcare reported final 48-week LATITUDE results showing long-acting injectable cabotegravir + rilpivirine cut cumulative regimen-failure risk nearly in half versus daily oral ART (22.8% vs 41.2%).
VF rates were 6.8% vs 28.2%; treatment-related failure 8.9% vs 28.1%; safety profiles were similar, with injection-site reactions most common.